抗体偶联药物国内研发现状及企业布局分析

抗体偶联药物(antibody-drug conjugates,ADC)由单克隆抗体和小分子细胞毒药物通过连接子偶联而成,因在血液瘤、实体瘤等临床治疗中被证明是一种极有前景的技术手段,已经成为国内外抗体药物研发的新热门方向.系统阐述了ADC药物开发及工业化生产中的核心五要素,对国内ADC的研发管线进行了梳理,并对参与A...

Domestic Research and Development Status of Antibody-drug Conjugates and Strategic Layout of Key Enterprises

Antibody-drug conjugates are immunoconjugates comprised of monoclonal antibodies tethered to a cytotoxic drug via a chemical linker.It has been proven to be a promising technical method in the clinical treatment of hematologic malignancies and solid tumors.Therefore,it has newly become one of the fastest growing areas in the researching and developing of anticancer drugs at home and overseas. Five key requirements of ADCs throughout the research and pharmacuetical manufacturing process were expatiated systematically,and the pipelines and strategic layout of major domestic companies were also analyzed in order to provide a reference for the R&D layout of ADCs for the emerging companies and industrial decision for regional government.